<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37267758</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-3618</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Seminars in immunology</Title><ISOAbbreviation>Semin Immunol</ISOAbbreviation></Journal><ArticleTitle>Systems analysis of human innate immunity in COVID-19.</ArticleTitle><Pagination><StartPage>101778</StartPage><MedlinePgn>101778</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.smim.2023.101778</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1044-5323(23)00069-6</ELocationID><Abstract><AbstractText>Recent developments in sequencing technologies, the computer and data sciences, as well as increasingly high-throughput immunological measurements have made it possible to derive holistic views on pathophysiological processes of disease and treatment effects directly in humans. We and others have illustrated that incredibly predictive data for immune cell function can be generated by single cell multi-omics (SCMO) technologies and that these technologies are perfectly suited to dissect pathophysiological processes in a new disease such as COVID-19, triggered by SARS-CoV-2 infection. Systems level interrogation not only revealed the different disease endotypes, highlighted the differential dynamics in context of disease severity, and pointed towards global immune deviation across the different arms of the immune system, but was already instrumental to better define long COVID phenotypes, suggest promising biomarkers for disease and therapy outcome predictions and explains treatment responses for the widely used corticosteroids. As we identified SCMO to be the most informative technologies in the vest to better understand COVID-19, we propose to routinely include such single cell level analysis in all future clinical trials and cohorts addressing diseases with an immunological component.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Systems Medicine, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE) e.V., Bonn, Germany; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Genomics &amp; Immunoregulation, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultze</LastName><ForeName>Joachim L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Systems Medicine, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE) e.V., Bonn, Germany; Genomics &amp; Immunoregulation, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany; PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE and University of Bonn, Bonn, Germany. Electronic address: Joachim.Schultze@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GRK2168 &#x2013; 272482170</GrantID><Agency>German Research Foundation (</Agency><Country/></Grant><Grant><GrantID>390873048</GrantID><Agency> Excellence Cluster ImmunoSensation2, project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Semin Immunol</MedlineTA><NlmUniqueID>9009458</NlmUniqueID><ISSNLinking>1044-5323</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013597" MajorTopicYN="N">Systems Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Innate immune system</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">Monocytes</Keyword><Keyword MajorTopicYN="N">NK cells</Keyword><Keyword MajorTopicYN="N">Neutrophils</Keyword><Keyword MajorTopicYN="N">Single cell multi-omics technologies</Keyword><Keyword MajorTopicYN="N">Systems immunology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>3</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37267758</ArticleId><ArticleId IdType="pmc">PMC10201327</ArticleId><ArticleId IdType="doi">10.1016/j.smim.2023.101778</ArticleId><ArticleId IdType="pii">S1044-5323(23)00069-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahilkar S., Agrawal S., Chaudhary S., Parikh S., Sonkar S.C., Verma D.K., et al. SARS-CoV-2 variants: Impact on biological and clinical outcome. Front Med (Lausanne) 2022;9 doi: 10.3389/fmed.2022.995960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.995960</ArticleId><ArticleId IdType="pmc">PMC9685312</ArticleId><ArticleId IdType="pubmed">36438034</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin D.A., Gulick R.M., Martinez F.J. Severe covid-19. N. Engl. J. Med. 2020;383:2451&#x2013;2460. doi: 10.1056/NEJMcp2009575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009575</ArticleId><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi R.T., Lynch J.B., Del Rio C. Mild or moderate Covid-19. N. Engl. J. Med. 2020;383:1757&#x2013;1766. doi: 10.1056/NEJMcp2009249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009249</ArticleId><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen J.H., Tomlinson C., Hollings S., Mizani M.A., Handy A., Akbari A., et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Lancet Digit Health. 2022;4:e542&#x2013;e557. doi: 10.1016/S2589-7500(22)00091-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00091-7</ArticleId><ArticleId IdType="pmc">PMC9179175</ArticleId><ArticleId IdType="pubmed">35690576</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S., et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017&#x2013;1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Turakhia Y., Thornlow B., Hinrichs A., McBroome J., Ayala N., Ye C., et al. Pandemic-scale phylogenomics reveals the SARS-CoV-2 recombination landscape. Nature. 2022;609:994&#x2013;997. doi: 10.1038/s41586-022-05189-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05189-9</ArticleId><ArticleId IdType="pmc">PMC9519458</ArticleId><ArticleId IdType="pubmed">35952714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., Collier D.A., Datir R.P., Ferreira I.A.T.M., Gayed S., Jahun A., et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277&#x2013;282. doi: 10.1038/s41586-021-03291-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Markarian N.M., Galli G., Patel D., Hemmings M., Nagpal P., Berghuis A.M., et al. Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiency. Front Microbiol. 2022;13 doi: 10.3389/fmicb.2022.933983.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.933983</ArticleId><ArticleId IdType="pmc">PMC9283111</ArticleId><ArticleId IdType="pubmed">35847101</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens D.M., Fauci A.S. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182:1077&#x2013;1092. doi: 10.1016/j.cell.2020.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.021</ArticleId><ArticleId IdType="pmc">PMC7428724</ArticleId><ArticleId IdType="pubmed">32846157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur B., Dubey P., Benitez J., Torres J.P., Reddy S., Shokar N., et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci. Rep. 2021;11:8562. doi: 10.1038/s41598-021-88130-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88130-w</ArticleId><ArticleId IdType="pmc">PMC8058064</ArticleId><ArticleId IdType="pubmed">33879826</ArticleId></ArticleIdList></Reference><Reference><Citation>Host Genetics Initiative COVID-19. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472&#x2013;477. doi: 10.1038/s41586-021-03767-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03767-x</ArticleId><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Made C.I., Simons A., Schuurs-Hoeijmakers J., van den Heuvel G., Mantere T., Kersten S., et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324:663&#x2013;673. doi: 10.1001/jama.2020.13719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.13719</ArticleId><ArticleId IdType="pmc">PMC7382021</ArticleId><ArticleId IdType="pubmed">32706371</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler-Laporte G., Povysil G., Kosmicki J.A., Cirulli E.T., Drivas T., Furini S., et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022;18 doi: 10.1371/journal.pgen.1010367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1010367</ArticleId><ArticleId IdType="pmc">PMC9632827</ArticleId><ArticleId IdType="pubmed">36327219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., COVID&#xa0;Human Genetic Effort, Cobat A., Casanova J.-L. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587&#x2013;598. doi: 10.1038/s41586-022-04447-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04447-0</ArticleId><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., Aschenbrenner A.C. COVID-19 and the human innate immune system. Cell. 2021;184:1671&#x2013;1692. doi: 10.1016/j.cell.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Frishberg A., Kooistra E., Nuesch-Germano M., Pecht T., Milman N., Reusch N., et al. Mature neutrophils and a NF-&#x3ba;B-to-IFN transition determine the unifying disease recovery dynamics in COVID-19. Cell Rep. Med. 2022;3 doi: 10.1016/j.xcrm.2022.100652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100652</ArticleId><ArticleId IdType="pmc">PMC9110324</ArticleId><ArticleId IdType="pubmed">35675822</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18 doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(881&#x2013;895) doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J., Reusch N., Paclik D., Ba&#xdf;ler K., Schlickeiser S., Zhang B., et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182(1419&#x2013;1440) doi: 10.1016/j.cell.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xe4;mer B., Knoll R., Bonaguro L., ToVinh M., Raabe J., Astaburuaga-Garc&#xed;a R., et al. Early IFN-&#x3b1; signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021;54(2650&#x2013;2669) doi: 10.1016/j.immuni.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch D., Dietrich O., Mari T., von Stillfried S., Ibarra I.L., Mittermaier M., et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;184(6243&#x2013;6261) doi: 10.1016/j.cell.2021.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.033</ArticleId><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Georg P., Astaburuaga-Garc&#xed;a R., Bonaguro L., Brumhard S., Michalick L., Lippert L.J., et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022;185(493&#x2013;512) doi: 10.1016/j.cell.2021.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.040</ArticleId><ArticleId IdType="pmc">PMC8712270</ArticleId><ArticleId IdType="pubmed">35032429</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson E., Reynolds G., Botting R.A., Calero-Nieto F.J., Morgan M.D., Tuong Z.K., et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nat. Med. 2021 doi: 10.1038/s41591-021-01329-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01329-2</ArticleId><ArticleId IdType="pmc">PMC8121667</ArticleId><ArticleId IdType="pubmed">33879890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajewsky N., Almouzni G., Gorski S.A., Aerts S., Amit I., Bertero M.G., et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature. 2020;587:377&#x2013;386. doi: 10.1038/s41586-020-2715-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2715-9</ArticleId><ArticleId IdType="pmc">PMC7656507</ArticleId><ArticleId IdType="pubmed">32894860</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L. Teaching &#x201c;big data&#x201d; analysis to young immunologists. Nat. Immunol. 2015;16:902&#x2013;905. doi: 10.1038/ni.3250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3250</ArticleId><ArticleId IdType="pubmed">26287590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaguro L., Schulte-Schrepping J., Ulas T., Aschenbrenner A.C., Beyer M., Schultze J.L. A guide to systems-level immunomics. Nat. Immunol. 2022;23:1412&#x2013;1423. doi: 10.1038/s41590-022-01309-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01309-9</ArticleId><ArticleId IdType="pubmed">36138185</ArticleId></ArticleIdList></Reference><Reference><Citation>Rood J.E., Maartens A., Hupalowska A., Teichmann S.A., Regev A. Impact of the Human Cell Atlas on medicine. Nat. Med. 2022;28:2486&#x2013;2496. doi: 10.1038/s41591-022-02104-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02104-7</ArticleId><ArticleId IdType="pubmed">36482102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., et al. SARS-CoV-2 Receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(1016&#x2013;1035) doi: 10.1016/j.cell.2020.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W., Huang N., B&#xe9;cavin C., Berg M., Queen R., Litvinukova M., et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020;26:681&#x2013;687. doi: 10.1038/s41591-020-0868-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N., P&#xe9;rez P., Kato T., Mikami Y., Okuda K., Gilmore R.C., et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat. Med. 2021;27:892&#x2013;903. doi: 10.1038/s41591-021-01296-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01296-8</ArticleId><ArticleId IdType="pmc">PMC8240394</ArticleId><ArticleId IdType="pubmed">33767405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler C.G.K., Miao V.N., Owings A.H., Navia A.W., Tang Y., Bromley J.D., et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell. 2021;184(4713&#x2013;4733) doi: 10.1016/j.cell.2021.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.023</ArticleId><ArticleId IdType="pmc">PMC8299217</ArticleId><ArticleId IdType="pubmed">34352228</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D., Mathian A., Miyara M., Mohr A., Anna F., Cla&#xeb;r L., et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 2021:13. doi: 10.1126/scitranslmed.abd2223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd2223</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua R.L., Lukassen S., Trump S., Hennig B.P., Wendisch D., Pott F., et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 2020;38:970&#x2013;979. doi: 10.1038/s41587-020-0602-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0602-4</ArticleId><ArticleId IdType="pubmed">32591762</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Abdullahi A., Ferreira I.A.T.M., Goonawardane N., Saito A., Kimura I., et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2013;714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant R.A., Morales-Nebreda L., Markov N.S., Swaminathan S., Querrey M., Guzman E.R., et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590:635&#x2013;641. doi: 10.1038/s41586-020-03148-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03148-w</ArticleId><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842&#x2013;844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.T., Park M.D., Del Valle D.M., Buckup M., Tabachnikova A., Thompson R.C., et al. A shift in lung macrophage composition is associated with COVID-19 severity and recovery. Sci. Transl. Med. 2022;14:eabn5168. doi: 10.1126/scitranslmed.abn5168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn5168</ArticleId><ArticleId IdType="pmc">PMC10117220</ArticleId><ArticleId IdType="pubmed">36103512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauters E., Van Mol P., Garg A.D., Jansen S., Van Herck Y., Vanderbeke L., et al. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res. 2021;0:1&#x2013;19. doi: 10.1038/s41422-020-00455-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-00455-9</ArticleId><ArticleId IdType="pmc">PMC8027624</ArticleId><ArticleId IdType="pubmed">33473155</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms J.C., Biermann J., Huang H., Wang Y., Nair A., Tagore S., et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595:114&#x2013;119. doi: 10.1038/s41586-021-03569-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03569-1</ArticleId><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorey T.M., Ziegler C.G.K., Heimberg G., Normand R., Yang Y., Segerstolpe &#xc5;., et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595:107&#x2013;113. doi: 10.1038/s41586-021-03570-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03570-8</ArticleId><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Carpp L.N., Miller H.E.R., Zager M., Newell E.W., Gottardo R. Single-cell immunology of SARS-CoV-2 infection. Nat. Biotechnol. 2022;40:30&#x2013;41. doi: 10.1038/s41587-021-01131-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01131-y</ArticleId><ArticleId IdType="pmc">PMC9414121</ArticleId><ArticleId IdType="pubmed">34931002</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll R., Schultze J.L., Schulte-Schrepping J. Monocytes and macrophages in COVID-19. Front Immunol. 2021;12 doi: 10.3389/fimmu.2021.720109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.720109</ArticleId><ArticleId IdType="pmc">PMC8335157</ArticleId><ArticleId IdType="pubmed">34367190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A.J., Lee M.J., Wei B., Parks B., Pi R., Mart&#xed;nez-Col&#xf3;n G.J., et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J. Exp. Med. 2021:218. doi: 10.1084/jem.20210582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210582</ArticleId><ArticleId IdType="pmc">PMC8210586</ArticleId><ArticleId IdType="pubmed">34128959</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Chen D., Yuan D., Lausted C., Choi J., Dai C.L., et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell. 2020;183(1479&#x2013;1495) doi: 10.1016/j.cell.2020.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvin A., Chapuis N., Dunsmore G., Goubet A.-G., Dubuisson A., Derosa L., et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182(1401&#x2013;1418) doi: 10.1016/j.cell.2020.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.002</ArticleId><ArticleId IdType="pmc">PMC7405878</ArticleId><ArticleId IdType="pubmed">32810439</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Wimmers F., Mok C.K.P., Perera R.A.P.M., Scott M., Hagan T., et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210&#x2013;1220. doi: 10.1126/science.abc6261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gressier E., Schulte-Schrepping J., Petrov L., Brumhard S., Stubbemann P., Hiller A., et al. CD4+ T cell calibration of APC optimizesantiviral CD8+ T cell immunity. Nat Immunol n.d.;in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">37188942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A.J., Courau T., Kuhn N.F., Hu K.H., Ray A., Chen W.S., et al. Global absence and targeting of protective immune states in severe COVID-19. Nature. 2021;591:124&#x2013;130. doi: 10.1038/s41586-021-03234-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03234-7</ArticleId><ArticleId IdType="pmc">PMC8567458</ArticleId><ArticleId IdType="pubmed">33494096</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst M.G.P., Vazquez S.E., Hartoularos G.C., Bastard P., Grant T., Bueno R., et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 2021;13:eabh2624. doi: 10.1126/scitranslmed.abh2624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.S., Park S., Jeong H.W., Ahn J.Y., Choi S.J., Lee H., et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 2020:5. doi: 10.1126/sciimmunol.abd1554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd1554</ArticleId><ArticleId IdType="pmc">PMC7402635</ArticleId><ArticleId IdType="pubmed">32651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Reusch N., De Domenico E., Bonaguro L., Schulte-Schrepping J., Ba&#xdf;ler K., Schultze J.L., et al. Neutrophils in COVID-19. Front Immunol. 2021;12 doi: 10.3389/fimmu.2021.652470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.652470</ArticleId><ArticleId IdType="pmc">PMC8027077</ArticleId><ArticleId IdType="pubmed">33841435</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner A.C., Mouktaroudi M., Kr&#xe4;mer B., Oestreich M., Antonakos N., Nuesch-Germano M., et al. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Med. 2021;13:7. doi: 10.1186/s13073-020-00823-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-020-00823-5</ArticleId><ArticleId IdType="pmc">PMC7805430</ArticleId><ArticleId IdType="pubmed">33441124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Wen Y., Xie X., Liu Y., Tan X., Cai Q., et al. Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell Disco. 2021;7:60. doi: 10.1038/s41421-021-00296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00296-9</ArticleId><ArticleId IdType="pmc">PMC8335717</ArticleId><ArticleId IdType="pubmed">34349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Rosin N.L., Arora R., Labit E., Jaffer A., Cao L., et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat. Med. 2022;28:201&#x2013;211. doi: 10.1038/s41591-021-01576-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01576-3</ArticleId><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>de Kleijn S., Langereis J.D., Leentjens J., Kox M., Netea M.G., Koenderman L., et al. IFN-&#x3b3;-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One. 2013;8 doi: 10.1371/journal.pone.0072249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072249</ArticleId><ArticleId IdType="pmc">PMC3756078</ArticleId><ArticleId IdType="pubmed">24015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Darcy C.J., Minigo G., Piera K.A., Davis J.S., McNeil Y.R., Chen Y., et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit. Care. 2014;18:R163. doi: 10.1186/cc14003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc14003</ArticleId><ArticleId IdType="pmc">PMC4261583</ArticleId><ArticleId IdType="pubmed">25084831</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., He B., Carver K., Vanheyningen D., Parkin B., Garmire L.X., et al. Heterogeneity of neutrophils and inflammatory responses in patients with COVID-19 and healthy controls. Front Immunol. 2022;13 doi: 10.3389/fimmu.2022.970287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.970287</ArticleId><ArticleId IdType="pmc">PMC9709423</ArticleId><ArticleId IdType="pubmed">36466858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro L.S., Migliari Branco L., Franklin B.S. Regulation of innate immune responses by platelets. Front Immunol. 2019;10:1320. doi: 10.3389/fimmu.2019.01320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01320</ArticleId><ArticleId IdType="pmc">PMC6579861</ArticleId><ArticleId IdType="pubmed">31244858</ArticleId></ArticleIdList></Reference><Reference><Citation>Koupenova M., Livada A.C., Morrell C.N. Platelet and megakaryocyte roles in innate and adaptive immunity. Circ. Res. 2022;130:288&#x2013;308. doi: 10.1161/CIRCRESAHA.121.319821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.319821</ArticleId><ArticleId IdType="pmc">PMC8852355</ArticleId><ArticleId IdType="pubmed">35050690</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardes J.P., Mishra N., Tran F., Bahmer T., Best L., Blase J.I., et al. Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. Immunity. 2020;53(1296&#x2013;1314) doi: 10.1016/j.immuni.2020.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.017</ArticleId><ArticleId IdType="pmc">PMC7689306</ArticleId><ArticleId IdType="pubmed">33296687</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas S., Hansson J., Klimmeck D., Loeffler D., Velten L., Uckelmann H., et al. Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell. 2015;17:422&#x2013;434. doi: 10.1016/j.stem.2015.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2015.07.007</ArticleId><ArticleId IdType="pubmed">26299573</ArticleId></ArticleIdList></Reference><Reference><Citation>Taus F., Salvagno G., Can&#xe8; S., Fava C., Mazzaferri F., Carrara E., et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler. Thromb. Vasc. Biol. 2020;40:2975&#x2013;2989. doi: 10.1161/ATVBAHA.120.315175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315175</ArticleId><ArticleId IdType="pmc">PMC7682791</ArticleId><ArticleId IdType="pubmed">33052054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkstr&#xf6;m N.K., Strunz B., Ljunggren H.-G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 2022;22:112&#x2013;123. doi: 10.1038/s41577-021-00558-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00558-3</ArticleId><ArticleId IdType="pmc">PMC8194386</ArticleId><ArticleId IdType="pubmed">34117484</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkstr&#xf6;m N.K., Ljunggren H.-G., Micha&#xeb;lsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat. Rev. Immunol. 2016;16:310&#x2013;320. doi: 10.1038/nri.2016.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.34</ArticleId><ArticleId IdType="pubmed">27121652</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski M., Tizian C., Ferreira-Gomes M., Niemeyer D., Jones T.C., Heinrich F., et al. Untimely TGF&#x3b2; responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600:295&#x2013;301. doi: 10.1038/s41586-021-04142-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04142-6</ArticleId><ArticleId IdType="pubmed">34695836</ArticleId></ArticleIdList></Reference><Reference><Citation>Malengier-Devlies B., Filtjens J., Ahmadzadeh K., Boeckx B., Vandenhaute J., De Visscher A., et al. Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates. Front Immunol. 2022;13 doi: 10.3389/fimmu.2022.861251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.861251</ArticleId><ArticleId IdType="pmc">PMC9581751</ArticleId><ArticleId IdType="pubmed">36275702</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C., Wu M., Huang B., Zhao R., Jin L., Fu B., et al. Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19. Genome Med. 2022;14:46. doi: 10.1186/s13073-022-01049-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-022-01049-3</ArticleId><ArticleId IdType="pmc">PMC9060844</ArticleId><ArticleId IdType="pubmed">35501841</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861&#x2013;880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Krovi S.H., Gapin L. Invariant natural killer T cell subsets-more than just developmental intermediates. Front Immunol. 2018;9:1393. doi: 10.3389/fimmu.2018.01393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01393</ArticleId><ArticleId IdType="pmc">PMC6019445</ArticleId><ArticleId IdType="pubmed">29973936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankerhold J., Giese S., Kolb P., Maul-Pavicic A., Voll R.E., G&#xf6;ppert N., et al. Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nat. Commun. 2022;13:5654. doi: 10.1038/s41467-022-32867-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32867-z</ArticleId><ArticleId IdType="pmc">PMC9513013</ArticleId><ArticleId IdType="pubmed">36163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanickam A., Kumar N.P., Pandiarajan A.N., Selvaraj N., Munisankar S., Renji R.M., et al. Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. Sci. Rep. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8511073</ArticleId><ArticleId IdType="pubmed">34642411</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Zhang Z., Koeken V.A.C.M., Kumar S., Aillaud M., Tsay H.-C., et al. Altered and allele-specific open chromatin landscape reveals epigenetic and genetic regulators of innate immunity in COVID-19. Cell Genom. 2022 doi: 10.1016/j.xgen.2022.100232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xgen.2022.100232</ArticleId><ArticleId IdType="pmc">PMC9715265</ArticleId><ArticleId IdType="pubmed">36474914</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Chen X., Dan J., Hu T., Hu Y., Liu S., et al. Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents. Signal Transduct. Target Ther. 2022;7:377. doi: 10.1038/s41392-022-01237-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01237-y</ArticleId><ArticleId IdType="pmc">PMC9666472</ArticleId><ArticleId IdType="pubmed">36379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., Durstenfeld M.S., Ho H.-E., Goldberg S.A., et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.-S., et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 2022;3 doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M., Apostolo D., Alb&#xe8; A., Crevola M., Errica N., Ratano G., et al. Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study. Front Immunol. 2022;13:1038227. doi: 10.3389/fimmu.2022.1038227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1038227</ArticleId><ArticleId IdType="pmc">PMC9807078</ArticleId><ArticleId IdType="pubmed">36601115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A., Koch R., Jukic A., Pfister A., Meyer M., R&#xf6;ssler A., et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163(495&#x2013;506) doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deveau T.-M., Munter S.E., Ryder D., Buck A., Beck-Engeser G., et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 2023:133. doi: 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Muri J., Cecchinato V., Cavalli A., Shanbhag A.A., Matkovic M., Biggiogero M., et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat. Immunol. 2023 doi: 10.1038/s41590-023-01445-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01445-w</ArticleId><ArticleId IdType="pmc">PMC10063443</ArticleId><ArticleId IdType="pubmed">36879067</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C., Boesl F., Goereci Y., Gerhard A., Schweitzer F., Schroeder M., et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav. Immun. 2023;109:139&#x2013;143. doi: 10.1016/j.bbi.2023.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC9841734</ArticleId><ArticleId IdType="pubmed">36657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K., Jamil R., Chowdhury A., Mukherjee M., Venegas C., Miyasaki K., et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir. J. 2023:61. doi: 10.1183/13993003.00970-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00970-2022</ArticleId><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat. Commun. 2022;13:5104. doi: 10.1038/s41467-022-32507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F., Blanco J., Capelli E., Castro-Marrero J., Steiner S., Murovska M., et al. Myalgic encephalomyelitis/chronic fatigue syndrome - evidence for an autoimmune disease. Autoimmun. Rev. 2018;17:601&#x2013;609. doi: 10.1016/j.autrev.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.01.009</ArticleId><ArticleId IdType="pubmed">29635081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth K.J., Scheibenbogen C., Paul F. An attempt to explain the neurological symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Transl. Med. 2021;19:471. doi: 10.1186/s12967-021-03143-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03143-3</ArticleId><ArticleId IdType="pmc">PMC8607226</ArticleId><ArticleId IdType="pubmed">34809664</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol. Med. 2021 doi: 10.1016/j.molmed.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come. Med Hypotheses. 2021;146 doi: 10.1016/j.mehy.2020.110469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110469</ArticleId><ArticleId IdType="pmc">PMC7836544</ArticleId><ArticleId IdType="pubmed">33401106</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M., Freitag H., Rudolf G., Seifert M., Doehner W., Scherbakov N., et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS. J. Transl. Med. 2022;20:138. doi: 10.1186/s12967-022-03346-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03346-2</ArticleId><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcom E.F., Nath A., Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain. 2021;144:3576&#x2013;3588. doi: 10.1093/brain/awab302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab302</ArticleId><ArticleId IdType="pmc">PMC8719840</ArticleId><ArticleId IdType="pubmed">34398188</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A., Lu P., Geraghty A.C., Song E., Lee M.-H., Wood J., et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185(2452&#x2013;2468) doi: 10.1016/j.cell.2022.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B., Boustani K., Ogger P.P., Papadaki A., Tonkin J., Orton C.M., et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity. 2022;55(542&#x2013;556) doi: 10.1016/j.immuni.2022.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.01.017</ArticleId><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Reed A., Desai S.R., Devaraj A., Faiez T.S., Laverty S., et al. A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae. Sci. Transl. Med. 2022;14:eabo5795. doi: 10.1126/scitranslmed.abo5795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5795</ArticleId><ArticleId IdType="pubmed">36383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon I.S., Li C., Son Y.M., Goplen N.P., Wu Y., Cassmann T., et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci. Immunol. 2021;6:eabk1741. doi: 10.1126/sciimmunol.abk1741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz A., Mendes-Frias A., Azarias-da-Silva M., Andr&#xe9; S., Oliveira A.I., Pires O., et al. Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+&#x3b2;7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nat. Commun. 2023;14:1772. doi: 10.1038/s41467-023-37368-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37368-1</ArticleId><ArticleId IdType="pmc">PMC10061413</ArticleId><ArticleId IdType="pubmed">36997530</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnat-Herresthal S., Schultze H., Shastry K.L., Manamohan S., Mukherjee S., Garg V., et al. Swarm Learning for decentralized and confidential clinical machine learning. Nature. 2021;594:265&#x2013;270. doi: 10.1038/s41586-021-03583-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03583-3</ArticleId><ArticleId IdType="pmc">PMC8189907</ArticleId><ArticleId IdType="pubmed">34040261</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., B&#xfc;ttner M., Becker M. Swarm immunology: harnessing blockchain technology and artificial intelligence in human immunology. Nat. Rev. Immunol. 2022;22:401&#x2013;403. doi: 10.1038/s41577-022-00740-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00740-1</ArticleId><ArticleId IdType="pmc">PMC9136788</ArticleId><ArticleId IdType="pubmed">35624333</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>